Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents


Vitae Pharmaceuticals, Inc.

Statements of Operations

 
  Year Ended December 31,  
 
  2013   2012  

Collaborative revenues

  $ 22,512,683   $ 22,347,827  

Operating expenses:

             

Research and development

    14,916,562     15,926,614  

General and administrative

    5,405,769     4,915,124  
           

Total operating expenses

    20,322,331     20,841,738  
           

Operating income

    2,190,352     1,506,089  

Other (expenses) income:

             

Other income

    327,391     243,000  

Interest income

    69,497     100,619  

Interest expense

    (1,425,342 )   (1,626,622 )
           

Total other (expenses) income

    (1,028,454 )   (1,283,003 )
           

Net income

  $ 1,161,898   $ 223,086  
           
           

Per share information:

             

Net income per common share:

             

Basic

  $ 0.00   $ 0.00  
           
           

Diluted

  $ 0.00   $ 0.00  
           
           

Weighted average number of common shares:

             

Basic

    12,955,471     12,476,508  
           
           

Diluted

    12,955,471     12,476,508  
           
           

Unaudited pro forma net income per common share:

             

Basic

  $ 0.01        

Diluted

  $ 0.00        

Unaudited pro forma weighted average number of common shares:

             

Basic

    231,265,212        

Diluted

    240,654,104        

   

The accompanying notes are an integral part of these financial statements.

F-4